4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 94 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q1 2023. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $367,883 | -22.6% | 21,401 | 0.0% | 0.00% | +50.0% |
| Q4 2022 | $475,316 | -75.9% | 21,401 | -91.3% | 0.00% | -83.3% |
| Q3 2022 | $1,971,000 | +15.2% | 245,123 | 0.0% | 0.01% | -53.8% |
| Q2 2022 | $1,711,000 | -53.8% | 245,123 | 0.0% | 0.03% | -42.2% |
| Q1 2022 | $3,706,000 | -31.1% | 245,123 | 0.0% | 0.04% | -16.7% |
| Q4 2021 | $5,378,000 | -27.5% | 245,123 | -10.9% | 0.05% | +74.2% |
| Q3 2021 | $7,421,000 | +12.0% | 275,123 | 0.0% | 0.03% | -16.2% |
| Q2 2021 | $6,625,000 | -44.7% | 275,123 | -0.4% | 0.04% | -43.1% |
| Q1 2021 | $11,986,000 | +398.6% | 276,294 | +376.4% | 0.06% | +242.1% |
| Q4 2020 | $2,404,000 | – | 58,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,007,413 | $68,887,429 | 2.52% |
| Opaleye Management Inc. | 314,000 | $5,397,660 | 1.62% |
| Deep Track Capital, LP | 2,278,107 | $39,160,659 | 1.61% |
| Casdin Capital, LLC | 1,070,000 | $18,393,300 | 1.52% |
| Eagle Health Investments LP | 437,911 | $7,527,690 | 1.46% |
| ACUTA CAPITAL PARTNERS, LLC | 104,753 | $1,800,704 | 1.33% |
| Octagon Capital Advisors LP | 499,996 | $8,594,931 | 1.24% |
| Soleus Capital Management, L.P. | 469,400 | $8,068,986 | 0.84% |
| Novo Holdings A/S | 700,000 | $12,033,000 | 0.79% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $67,692,742 | 0.32% |